Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

If you’re interested in the biotech industry, here are some ideas to get you started in your search.

We ran a screen on the biotech industry for stocks rallying above their 20-day, 50-day and 200-day moving averages. We screened these strong performers for those that also have the strongest net institutional buying over the current quarter.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬


We also created a price-weighted index of the stocks mentioned below and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Click to enlarge

Do you agree with hedge funds on these names? Use this list as a starting point for your own analysis.

List sorted by distance from 20-day SMA.

1. Idenix Pharmaceuticals Inc. (NASDAQ:IDIX): Engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. Market cap of $867.62M. The stock is currently trading at 18.46% above its 20-Day SMA, 37.91% above its 50-Day SMA, and 63.68% above its 200-Day SMA. Institutional shares purchased over the current quarter at 2.6M, which represents 4.10% of the company's 63.49M share float. The stock is a short squeeze candidate, with a short float at 7.45% (equivalent to 6.73 days of average volume). The stock has had a couple of great days, gaining 21.42% over the last week.

2. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Focuses on the discovery, development and commercialization of small-molecule drugs for the treatment of cancer. Market cap of $1.58B. The stock is currently trading at 7.63% above its 20-Day SMA, 12.89% above its 50-Day SMA, and 27.10% above its 200-Day SMA. Institutional shares purchased over the current quarter at 2.7M, which represents 2.12% of the company's 127.13M share float. The stock is a short squeeze candidate, with a short float at 12.66% (equivalent to 5.06 days of average volume). The stock has had a couple of great days, gaining 9.88% over the last week.

3. Repros Therapeutics Inc. (NASDAQ:RPRX): Biotechnology Industry. Market cap of $62.09M. The stock is currently trading at 7.30% above its 20-Day SMA, 16.87% above its 50-Day SMA, and 0.26% above its 200-Day SMA. Institutional shares purchased over the current quarter at 347.3K, which represents 4.38% of the company's 7.93M share float. The stock is a short squeeze candidate, with a short float at 7.62% (equivalent to 20.95 days of average volume). The stock has had a good month, gaining 14.55%.

4. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Market cap of $3.94B. The stock is currently trading at 7.14% above its 20-Day SMA, 6.54% above its 50-Day SMA and 22.10% above its 200-Day SMA. Institutional shares purchased over the current quarter at 3.0M, which represents 2.64% of the company's 113.78M share float. The stock is a short squeeze candidate, with a short float at 6.59% (equivalent to 8.07 days of average volume). The stock has had a couple of great days, gaining 7.07% over the last week.

5. VIVUS Inc. (NASDAQ:VVUS): Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Market cap of $935.02M. The stock is currently trading at 6.98% above its 20-Day SMA, 16.11% above its 50-Day SMA and 32.34% above its 200-Day SMA. Institutional shares purchased over the current quarter at 9.8M, which represents 17.10% of the company's 57.30M share float. The stock is a short squeeze candidate, with a short float at 19.08% (equivalent to 11.43 days of average volume). The stock has had a couple of great days, gaining 12.63% over the last week.

6. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): Engages in the discovery and development of cancer therapeutics. Market cap of $729.22M. The stock is currently trading at 5.27% above its 20-Day SMA, 5.90% above its 50-Day SMA and 2.65% above its 200-Day SMA. Institutional shares purchased over the current quarter at 767.5K, which represents 2.40% of the company's 31.92M share float. The stock is a short squeeze candidate, with a short float at 6.32% (equivalent to 11.42 days of average volume). The stock has had a couple of great days, gaining 12.61% over the last week.

7. Theravance Inc. (NASDAQ:THRX): Engages in the discovery, development and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections and central nervous system (NYSE:CNS)/pain. Market cap of $1.99B. The stock is currently trading at 5.20% above its 20-Day SMA, 8.42% above its 50-Day SMA and 4.21% above its 200-Day SMA. Institutional shares purchased over the current quarter at 1.5M, which represents 4.14% of the company's 36.24M share float. The stock is a short squeeze candidate, with a short float at 9.64% (equivalent to 15.74 days of average volume). The stock has had a couple of great days, gaining 17.03% over the last week.

8. BioSante Pharmaceuticals, Inc. (BPAX): Develops products for female sexual health and oncology. Market cap of $277.23M. The stock is currently trading at 4.48% above its 20-Day SMA, 4.16% above its 50-Day SMA and 1.09% above its 200-Day SMA. Institutional shares purchased over the current quarter at 7.0M, which represents 6.60% of the company's 106.11M share float. The stock is a short squeeze candidate, with a short float at 18.42% (equivalent to 10.54 days of average volume). The stock has had a couple of great days, gaining 13.51% over the last week.

*Institutional data sourced from Fidelity, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Source: 8 Rallying Biotech Stocks Being Bought Up By Hedge Funds